Background Lung cancer is the leading cause of cancer death worldwide among both men and women. 1 Only 14% to 18% of all patients with lung cancer remain alive 5 years after diagnosis. 2 , 3 The treatment strategies for stages I, II, IIIb (T4N2
Search Results
Comparison of Treatment Strategies for Patients With Clinical Stage T1–3/N2 Lung Cancer
Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang
Barriers and Facilitators Impacting Lung Cancer Screening Uptake Among Black Veterans: A Qualitative Study
Neelima Navuluri, Tiera Lanford, Abigail Shapiro, Govind Krishnan, Angela B. Johnson, Isaretta L. Riley, Leah L. Zullig, Christopher E. Cox, and Scott Shofer
Background Lung cancer is the most common cause of cancer mortality in the United States, with Black males having the highest age-adjusted incidence and mortality among all racial and ethnic groups. 1 – 3 Annual low-dose CT (LDCT) scans allow
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non–Small Cell Lung Cancer
Stephen J. Bagley, Suzanna Talento, Nandita Mitra, Neal J. Meropol, Roger B. Cohen, Corey J. Langer, and Anil Vachani
Background For patients with advanced non–small cell lung cancer (NSCLC) whose tumors do not harbor an actionable genomic alteration or have PD-L1 expression (tumor proportion score ≥50%), a platinum-based chemotherapy doublet remains a standard
Overuse of Diagnostic Brain Imaging Among Patients With Stage IA Non–Small Cell Lung Cancer
Michael G. Milligan, Angel M. Cronin, Yolonda Colson, Kenneth Kehl, Debra N. Yeboa, Deborah Schrag, and Aileen B. Chen
Background The brain is a common site of metastasis for non–small cell lung cancer (NSCLC), and many patients undergo brain imaging with MRI or CT before definitive treatment. The hope is that early detection of brain metastases can expedite
Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer
Karen L. Reckamp
“There is a growing list of approved targets and therapies included in the 2018 NCCN Guidelines for Non–Small Cell Lung Cancer [NSCLC] as well as emerging targets. Why does this matter? Because targeted therapies improve survival,” said Karen L
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr., Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Non–Small Cell Lung Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non–Small Cell
Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry
Julian C. Hong, Matthew J. Boyer, Daphna Y. Spiegel, Christina D. Williams, Betty C. Tong, Scott L. Shofer, Michael J. Moravan, Michael J. Kelley, and Joseph K. Salama
Background Accurate initial staging is critical for appropriate management of small cell lung cancer (SCLC) because of stark differences in management and prognosis. Standard therapy for limited-stage SCLC (LS-SCLC) in patients with good performance
Association Between Treatment Facility Volume, Therapy Types, and Overall Survival in Patients With Stage IIIA Non–Small Cell Lung Cancer
Anuhya Kommalapati, Sri Harsha Tella, Adams Kusi Appiah, Lynette Smith, and Apar Kishor Ganti
Background Lung cancer is the leading cause of cancer-related death in the United States, attributed to approximately 44.7 deaths per 100,000 persons annually. 1 An estimated 234,000 cases were newly diagnosed in 2018 in the United States, with 154
New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer
Presented by: Gregory J. Riely
Recent advancements in targeted therapies for metastatic non–small cell lung cancer (NSCLC) have been remarkable, with multiple new approvals by the FDA in the past year alone. During the NCCN 2024 Annual Conference, Gregory J. Riely, MD, PhD
Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling
Adam C. Powell, Elifnur Yay Donderici, Nicole J. Zhang, Shaun P. Forbes, Julie Wiedower, Amy C. McNeal, and Mark D. Hiatt
Background The optimal first-line approach to treating non–small cell lung cancer (NSCLC) varies in accordance with a patient’s biomarkers. Comprehensive genomic profiling (CGP) tests can be used to determine the course of first-line treatment
